Drug Profile

PBI 220

Alternative Names: CMG2-Fc; PBI-220

Latest Information Update: 28 Apr 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Planet Biotechnology
Class Antibacterials; Immunoglobulin Fc fragments; Recombinant fusion proteins
Mechanism of Action Anthrax toxin inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes
Available For Licensing Yes

28 Apr 2025 No recent reports of development identified for preclinical development in Anthrax in USA
28 Apr 2025 No recent reports of development identified for preclinical development in Anthrax(Prevention) in USA
18 Mar 2021 Planet Biotechnology is seeking funding for the clinical testing of PBI 220 as of 18 Mar 2021. https://www.planetbiotechnology.com/

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com